AGILISIUM
Insights. Humanity. Impact.

Prior Authorization AI

AI-powered prior authorization prediction engine that forecasts approval outcomes before submission, enabling access teams to intervene early and accelerate therapy initiation for eligible patients.

Business Challenges

Payer policies shift frequently while Market Access teams gain visibility into authorization risk only after submissions fail, forcing reactive remediation that delays patient starts and drives revenue exposure.

Key Capabilities

- Pre-submission approval prediction using AI models trained on patient context, historical payer decisions, and policy patterns

- Early risk flagging for high-risk cases with specific documentation gaps and evidence alignment recommendations

- Payer-specific approval patterns across geographies with AI-driven recommendations for alternate pathways and timing strategies

Business Impact

» **30–50% reduction in time-to-therapy by resolving access risks before submission**

» **20–35% fewer prior authorization denials through proactive documentation alignment**

» **15–25% increase in Market Access team efficiency via intelligent case prioritization**

Trusted by 25+ F500/G2000 Life Sciences Clients

AMGEN

Thermo Fisher
SCIENTIFIC

REGENERON

Genmab

ucb

ABBOTT

www.agilisium.com   sales@agilisium.com